| Year |
Citation |
Score |
| 2023 |
Dietrich C, Trub A, Ahn A, Taylor M, Ambani K, Chan KT, Lu KH, Mahendra CA, Blyth C, Coulson R, Ramm S, Watt AC, Matsa SK, Bisi J, Strum J, ... ... Goel S, et al. INX-315, a selective CDK2 inhibitor, induces cell cycle arrest and senescence in solid tumors. Cancer Discovery. PMID 38047585 DOI: 10.1158/2159-8290.CD-23-0954 |
0.422 |
|
| 2023 |
Tolaney SM, Goel S, Nadal J, Denys H, Borrego MR, Litchfield LM, Liu J, Appiah AK, Chen Y, Andre F. Overall survival and exploratory biomarker analyses of abemaciclib plus trastuzumab with or without fulvestrant vs trastuzumab plus chemotherapy in HR+, HER2+ metastatic breast cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 37906649 DOI: 10.1158/1078-0432.CCR-23-1209 |
0.337 |
|
| 2023 |
Tolaney SM, Goel S, Appiah AK, Huynh T, Chen Y, André F. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer: plain language summary of the monarcHER study. Future Oncology (London, England). PMID 37788154 DOI: 10.2217/fon-2023-0078 |
0.349 |
|
| 2023 |
Ali LR, Garrido-Castro AC, Lenehan PJ, Bollenrucher N, Stump CT, Dougan M, Goel S, Shapiro GI, Tolaney SM, Dougan SK. PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer. The Journal of Experimental Medicine. 220. PMID 36688919 DOI: 10.1084/jem.20220729 |
0.305 |
|
| 2022 |
Goel S, Chandarlapaty S. Emerging Therapies for Breast Cancer. Cold Spring Harbor Perspectives in Medicine. PMID 36617643 DOI: 10.1101/cshperspect.a041333 |
0.386 |
|
| 2022 |
Goel S, Tan AR, Rugo HS, Aftimos P, Andrić Z, Beelen A, Zhang J, Yi JS, Malik R, O'Shaughnessy J. Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2. Future Oncology (London, England). PMID 36135712 DOI: 10.2217/fon-2022-0773 |
0.345 |
|
| 2022 |
Pernas S, Guerriero JL, Naumenko S, Goel S, Regan MM, Hu J, Harrison BT, Lynce F, Lin NU, Partridge A, Morikawa A, Hutchinson J, Mittendorf EA, Sokolov A, Overmoyer B. Early on-treatment transcriptional profiling as a tool for improving pathological response prediction in HER2-positive inflammatory breast cancer. Therapeutic Advances in Medical Oncology. 14: 17588359221113269. PMID 35923923 DOI: 10.1177/17588359221113269 |
0.344 |
|
| 2022 |
Wander SA, O'Brien N, Litchfield LM, O'Dea D, Morato Guimaraes C, Slamon DJ, Goel S. Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib. The Oncologist. PMID 35917168 DOI: 10.1093/oncolo/oyac138 |
0.394 |
|
| 2022 |
Goel S, Bergholz JS, Zhao JJ. Targeting CDK4 and CDK6 in cancer. Nature Reviews. Cancer. PMID 35304604 DOI: 10.1038/s41568-022-00456-3 |
0.631 |
|
| 2022 |
Watt AC, Goel S. Cellular mechanisms underlying response and resistance to CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer. Breast Cancer Research : Bcr. 24: 17. PMID 35248122 DOI: 10.1186/s13058-022-01510-6 |
0.419 |
|
| 2021 |
Bergholtz H, Carter JM, Cesano A, Cheang MCU, Church SE, Divakar P, Fuhrman CA, Goel S, Gong J, Guerriero JL, Hoang ML, Hwang ES, Kuasne H, Lee J, Liang Y, et al. Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx Digital Spatial Profiler. Cancers. 13. PMID 34503266 DOI: 10.3390/cancers13174456 |
0.346 |
|
| 2021 |
Watt AC, Cejas P, DeCristo MJ, Metzger-Filho O, Lam EYN, Qiu X, BrinJones H, Kesten N, Coulson R, Font-Tello A, Lim K, Vadhi R, Daniels VW, Montero J, Taing L, ... ... Goel S, et al. CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity. Nature Cancer. 2: 34-48. PMID 33997789 DOI: 10.1038/s43018-020-00135-y |
0.626 |
|
| 2021 |
Alomran R, White M, Bruce M, Bressel M, Roache S, Karroum L, Hanna GG, Siva S, Goel S, David S. Stereotactic radiotherapy for oligoprogressive ER-positive breast cancer (AVATAR). Bmc Cancer. 21: 303. PMID 33757458 DOI: 10.1186/s12885-021-08042-w |
0.394 |
|
| 2020 |
Tolaney SM, Wardley AM, Zambelli S, Hilton JF, Troso-Sandoval TA, Ricci F, Im SA, Kim SB, Johnston SR, Chan A, Goel S, Catron K, Chapman SC, Price GL, Yang Z, et al. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial. The Lancet. Oncology. PMID 32353342 DOI: 10.1016/S1470-2045(20)30112-1 |
0.446 |
|
| 2020 |
Bui KT, Willson ML, Goel S, Beith J, Goodwin A. Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer. The Cochrane Database of Systematic Reviews. 3: CD013538. PMID 32141074 DOI: 10.1002/14651858.Cd013538 |
0.4 |
|
| 2020 |
Goel S, Brauer HA, Ren Y, Gorman K, Osmani W, Pittenger J, Andrews C, Richardson ET, Mittendorf EA, Winer EP, Schnitt S, Tolaney SM. Abstract P4-06-01: Using multi-omic profiling to unravel the complexity of triple-negative breast cancer (TNBC) Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P4-06-01 |
0.425 |
|
| 2020 |
Herold CI, Trippa L, Li T, Do K, Bardia A, Anderson L, Montazeri K, Pittenger J, Andrews C, Mittendorf EA, Goel S, Winer EP, Shapiro GI, Tolaney SM. Abstract P3-14-03: A phase 1b study of the CDK4/6 inhibitor ribociclib in combination with the PD-1 inhibitor spartalizumab in patients with hormone receptor-positive metastatic breast cancer (HR+ MBC) and metastatic ovarian cancer (MOC) Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P3-14-03 |
0.425 |
|
| 2020 |
Tolaney S, Wardley AM, Zambelli S, Hilton J, Troso-Sandoval T, Ricci F, Im S, Kim S, Johnston S, Chan A, Goel S, Catron K, Yang Z, Gianford M, Price G, et al. Abstract P3-11-10: Health-related quality of life (HRQoL) in monarcHER: Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in HR+, HER2+ advanced breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P3-11-10 |
0.381 |
|
| 2019 |
Goel S, Tolaney SM. CDK4/6 inhibitors in breast cancer: a role in triple-negative disease? The Lancet. Oncology. PMID 31575504 DOI: 10.1016/S1470-2045(19)30627-8 |
0.465 |
|
| 2019 |
Goel S, Pernas S, Tan-Wasielewski Z, Barry WT, Bardia A, Rees R, Andrews C, Tahara RK, Trippa L, Mayer EL, Winer EP, Spring LM, Tolaney SM. Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial. Clinical Breast Cancer. PMID 31235441 DOI: 10.1016/J.Clbc.2019.05.010 |
0.496 |
|
| 2019 |
Spring L, Goel S, Sutherland S, Supko JG, Juric D, Isakoff SJ, Mayer EL, Moy B, Tolaney SM, Bardia A. Trastuzumab emtansine (T-DM1) and ribociclib, an oral inhibitor of cyclin dependent kinase 4 and 6 (CDK 4/6), for patients with metastatic HER2-positive breast cancer. Journal of Clinical Oncology. 37: 1028-1028. DOI: 10.1200/Jco.2019.37.15_Suppl.1028 |
0.462 |
|
| 2019 |
Pernas S, Goel S, Harrison B, Hu J, Johnson N, Regan M, Chichester L, Nakhlis F, Schlosnagle E, Winship G, Guerriero J, Parsons H, Mittendorf E, Overmoyer B. Abstract PD3-08: Assessment of the tumor immune environment in inflammatory breast cancer treated with neoadjuvant dual-HER2 blockade Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-Pd3-08 |
0.405 |
|
| 2019 |
Goel S, Spring L, Rees R, Andrews C, Tahara R, Mayer E, Bardia A, Winer E, Tolaney S. Abstract P6-18-10: A phase 1b/2 study of ribociclib plus trastuzumab for the treatment of advanced, treatment-refractory HER2-positive breast cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P6-18-10 |
0.469 |
|
| 2019 |
Pernas S, Goel S, Johnson NT, Harrison BT, Guerriero JL, Hu J, Winship G, Sokolov A, Regan MM, Mittendorf EA, Overmoyer B. Early on-treatment vs pre-treatment tumour transcriptomes as predictors of response to neoadjuvant therapy for HER2-positive inflammatory breast cancer Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz239.031 |
0.419 |
|
| 2018 |
Goel S, DeCristo MJ, McAllister SS, Zhao JJ. CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest. Trends in Cell Biology. PMID 30061045 DOI: 10.1016/J.Tcb.2018.07.002 |
0.659 |
|
| 2018 |
Li J, Choi PS, Chaffer CL, Labella K, Hwang JH, Giacomelli AO, Kim JW, Ilic N, Doench JG, Ly SH, Dai C, Hagel K, Hong AL, Gjoerup O, Goel S, et al. An alternative splicing switch in FLNB promotes the mesenchymal cell state in human breast cancer. Elife. 7. PMID 30059005 DOI: 10.7554/Elife.37184 |
0.601 |
|
| 2018 |
Pernas S, Tolaney SM, Winer EP, Goel S. CDK4/6 inhibition in breast cancer: current practice and future directions. Therapeutic Advances in Medical Oncology. 10: 1758835918786451. PMID 30038670 DOI: 10.1177/1758835918786451 |
0.536 |
|
| 2018 |
Li J, Choi PS, Chaffer CL, Labella K, Hwang JH, Giacomelli AO, Kim JW, Ilic N, Doench JG, Ly SH, Dai C, Hagel K, Hong AL, Gjoerup O, Goel S, et al. Author response: An alternative splicing switch in FLNB promotes the mesenchymal cell state in human breast cancer Elife. DOI: 10.7554/Elife.37184.034 |
0.414 |
|
| 2018 |
DeCristo MJ, Goel S, Watt AC, BrinJones H, Sceneay J, Li BB, Khan N, Ubellacker JM, Xie S, Metzger-Filho O, Hoog J, Ellis MJ, Ma C, Ramm S, Krop IE, et al. Abstract B04: CDK4/6 inhibition triggers an antitumor immune response Cancer Immunology Research. 6. DOI: 10.1158/2326-6074.Tumimm17-B04 |
0.465 |
|
| 2017 |
Goel S, DeCristo MJ, Watt AC, BrinJones H, Sceneay J, Li BB, Khan N, Ubellacker JM, Xie S, Metzger-Filho O, Hoog J, Ellis MJ, Ma CX, Ramm S, Krop IE, et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature. PMID 28813415 DOI: 10.1038/Nature23465 |
0.621 |
|
| 2017 |
Zhao Y, Ting K, Li J, Cogger VC, Chen J, Johansson-Percival A, Ngiow SF, Holst J, Grau GER, Goel S, Moller T, Dejana E, McCaughan GW, Smyth MJ, Ganss R, et al. Targeting vascular endothelial-cadherin in tumor-associated blood vessels promotes T cell-mediated immunotherapy. Cancer Research. PMID 28655790 DOI: 10.1158/0008-5472.Can-16-3129 |
0.337 |
|
| 2017 |
Kodack DP, Askoxylakis V, Ferraro GB, Sheng Q, Badeaux M, Goel S, Qi X, Shankaraiah R, Cao ZA, Ramjiawan RR, Bezwada D, Patel B, Song Y, Costa C, Naxerova K, et al. The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation. Science Translational Medicine. 9. PMID 28539475 DOI: 10.1126/Scitranslmed.Aal4682 |
0.443 |
|
| 2017 |
Garrido-Castro AC, Goel S. CDK4/6 Inhibition in Breast Cancer: Mechanisms of Response and Treatment Failure. Current Breast Cancer Reports. 9: 26-33. PMID 28479958 DOI: 10.1007/S12609-017-0232-0 |
0.474 |
|
| 2017 |
Hydbring P, Wang Y, Fassl A, Li X, Matia V, Otto T, Choi YJ, Sweeney KE, Suski JM, Yin H, Bogorad RL, Goel S, Yuzugullu H, Kauffman KJ, Yang J, et al. Cell-Cycle-Targeting MicroRNAs as Therapeutic Tools against Refractory Cancers. Cancer Cell. 31: 576-590.e8. PMID 28399412 DOI: 10.1016/J.Ccell.2017.03.004 |
0.591 |
|
| 2017 |
Tolaney SM, Bourayou N, Goel S, Hossain A, Andre F. A phase II randomized study to compare abemaciclib plus trastuzumab with or without fulvestrant to standard of care chemotherapy plus trastuzumab in hormone receptor positive, HER2-positive advanced breast cancer (monarcHER). Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.Tps1109 |
0.526 |
|
| 2017 |
Spring L, Goel S, Juric D, Isakoff SJ, Haddad S, Habin KR, Krop IE, Moy B, Tolaney SM, Bardia A. Trastuzumab emtansine (T-DM1) and ribociclib, an oral inhibitor of cyclin dependent kinase 4 and 6 (CDK 4/6), for patients with metastatic HER2-positive breast cancer: Phase 1b clinical trial. Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.Tps1106 |
0.517 |
|
| 2017 |
Filho OM, Goel S, Barry WT, Hamilton EP, Tolaney SM, Yardley DA, Rees R, Demeo M, Mills C, Hafner M, Winer EP, Zhao J, Krop IE. A mouse-human phase I co-clinical trial of taselisib in combination with TDM1 in advanced HER2-positive breast cancer (MBC). Journal of Clinical Oncology. 35: 1030-1030. DOI: 10.1200/Jco.2017.35.15_Suppl.1030 |
0.606 |
|
| 2017 |
Jacene H, Overmoyer B, Schlosnagle E, Abbott A, Yeh E, Paolino J, Goel S, Culhane A, Bellon J, Nakhlis F, Hirshfield-Bartek J, Abbeele AVd. Abstract OT2-02-03: Pilot study of zirconium-89 bevacizumab positron emission tomography for imaging angiogenesis in patients with inflammatory breast carcinoma receiving preoperative chemotherapy Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-Ot2-02-03 |
0.404 |
|
| 2017 |
Overmoyer B, Goel S, Regan M, Hirshfield-Bartek J, Schlosnagel E, Yeh E, Qin L, Bellon J, Nakhlis F, Jacene H, Winer E. Abstract OT1-01-07: A phase 2 study of eribulin followed by doxorubicin and cyclophosphamide as preoperative therapy for HER2-negative inflammatory breast cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-Ot1-01-07 |
0.439 |
|
| 2017 |
Ferraro GB, Kodack DP, Askoxylakis V, Sheng Q, Badeaux M, Goel S, Qi X, Shankaraiah R, Cao AZ, Ramjiawan RR, Bezwada D, Patel B, Song Y, Costa C, Naxerova K, et al. Abstract 5008: The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation Cancer Research. 77: 5008-5008. DOI: 10.1158/1538-7445.Am2017-5008 |
0.458 |
|
| 2017 |
DeCristo MJ, Goel S, Watt AC, BrinJones H, Sceneay J, Li B, Ubellacker JM, Xie S, Ramm S, Kim H, McAllister SS, Zhao JJ. Abstract 1634: CDK4/6 inhibition directly enhances an anti-tumor immune response in breast cancer Cancer Research. 77: 1634-1634. DOI: 10.1158/1538-7445.Am2017-1634 |
0.47 |
|
| 2016 |
Goel S, Zhao JJ. CDK4/6 inhibition: the late harvest cycle begins. Oncotarget. PMID 27391058 DOI: 10.18632/Oncotarget.9576 |
0.635 |
|
| 2016 |
Goel S, Krop IE. PIK3CA mutations in HER2-positive breast cancer - an ongoing conundrum. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. PMID 27358378 DOI: 10.1093/Annonc/Mdw246 |
0.412 |
|
| 2016 |
Ni J, Ramkissoon SH, Xie S, Goel S, Stover DG, Guo H, Luu V, Marco E, Ramkissoon LA, Kang YJ, Hayashi M, Nguyen QD, Ligon AH, Du R, Claus EB, et al. Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. Nature Medicine. PMID 27270588 DOI: 10.1038/Nm.4120 |
0.667 |
|
| 2016 |
Goel S, Wang Q, Watt AC, Tolaney SM, Dillon DA, Li W, Ramm S, Palmer AC, Yuzugullu H, Varadan V, Tuck D, Harris LN, Wong KK, Liu XS, Sicinski P, et al. Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors. Cancer Cell. 29: 255-269. PMID 26977878 DOI: 10.1016/J.Ccell.2016.02.006 |
0.674 |
|
| 2016 |
Tolaney SM, Bourayou N, Goel S, Forrester T, André F. monarcHER: A phase 2 randomized open-label study of abemaciclib plus trastuzumab (T) with or without fulvestrant (F) compared to standard-of-care chemotherapy of physician's choice plus T in women with HR + , HER2+ advanced breast cancer Annals of Oncology. 27. DOI: 10.1093/Annonc/Mdw365.93 |
0.382 |
|
| 2015 |
Tolaney SM, Boucher Y, Duda DG, Martin JD, Seano G, Ancukiewicz M, Barry WT, Goel S, Lahdenrata J, Isakoff SJ, Yeh ED, Jain SR, Golshan M, Brock J, Snuderl M, et al. Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients. Proceedings of the National Academy of Sciences of the United States of America. 112: 14325-14330. PMID 26578779 DOI: 10.1073/Pnas.1518808112 |
0.419 |
|
| 2015 |
Goel S, Winer EP. POINT: HER2-Targeted Combinations in Advanced HER2-Positive Breast Cancer. Oncology (Williston Park, N.Y.). 29. PMID 26573058 |
0.351 |
|
| 2015 |
Tiwari V, Pande SC, Verma K, Goel S. Spinal metastasis of breast cancer presenting after 25 years: An extremely rare presentation. The Gulf Journal of Oncology. 1: 24-7. PMID 26499826 |
0.346 |
|
| 2015 |
Swami U, Shah U, Goel S. Eribulin in Cancer Treatment. Marine Drugs. 13: 5016-58. PMID 26262627 DOI: 10.3390/md13085016 |
0.354 |
|
| 2015 |
Tiwari R, Pandey SK, Goel S, Bhatia V, Shukla S, Jing X, Dhanasekaran SM, Ateeq B. SPINK1 promotes colorectal cancer progression by downregulating Metallothioneins expression. Oncogenesis. 4: e162. PMID 26258891 DOI: 10.1038/oncsis.2015.23 |
0.352 |
|
| 2015 |
Goel S, Krop IE. Deciphering the role of phosphatidylinositol 3-kinase mutations in human epidermal growth factor receptor 2-positive breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 1407-9. PMID 25800754 DOI: 10.1200/Jco.2014.60.0742 |
0.506 |
|
| 2015 |
Ager EI, Kozin SV, Kirkpatrick ND, Seano G, Kodack DP, Askoxylakis V, Huang Y, Goel S, Snuderl M, Muzikansky A, Finkelstein DM, Dransfield DT, Devy L, Boucher Y, Fukumura D, et al. Blockade of MMP14 activity in murine breast carcinomas: implications for macrophages, vessels, and radiotherapy. Journal of the National Cancer Institute. 107. PMID 25710962 DOI: 10.1093/Jnci/Djv017 |
0.311 |
|
| 2015 |
Goel S, Guo H, Barry W, Murray B, Lynch J, Bastick P, Chantrill L, Kiely B, Bell R, Abdi E, Rutovitz J, Asghari R, Sullivan A, Harrison M, Kohonen-Corish M, et al. Abstract P4-15-02: Clinical, biochemical, and genomic predictors of trastuzumab-related cardiotoxicity: Results of CATS Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P4-15-02 |
0.375 |
|
| 2015 |
Goel S, Tolaney S. Optimizing the Management of Metastatic HER2-Positive Breast Cancer Current Breast Cancer Reports. 7: 190-202. DOI: 10.1007/S12609-015-0191-2 |
0.426 |
|
| 2015 |
Lim E, Goel S, Winer EP. Adjuvant chemotherapy in breast cancer Breast Disease: Comprehensive Management. 335-351. DOI: 10.1007/978-1-4939-1145-5_23 |
0.347 |
|
| 2013 |
Goel S, Gupta N, Walcott BP, Snuderl M, Kesler CT, Kirkpatrick ND, Heishi T, Huang Y, Martin JD, Ager E, Samuel R, Wang S, Yazbek J, Vakoc BJ, Peterson RT, et al. Effects of vascular-endothelial protein tyrosine phosphatase inhibition on breast cancer vasculature and metastatic progression. Journal of the National Cancer Institute. 105: 1188-201. PMID 23899555 DOI: 10.1093/Jnci/Djt164 |
0.374 |
|
| 2013 |
Huang Y, Goel S, Duda DG, Fukumura D, Jain RK. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Research. 73: 2943-8. PMID 23440426 DOI: 10.1158/0008-5472.Can-12-4354 |
0.356 |
|
| 2013 |
Boucher Y, Martin JD, Tolaney SM, Ancukiewicz M, Seano G, Goel S, Yeh E, Meyer JE, Isakoff SJ, Duda DG, Winer EP, Krop IE, Jain RK. Differential changes in tissue biomarkers after bevacizumab (BEV) alone in a neoadjuvant study of BEV and chemotherapy in ER+ breast cancer (BC) versus triple-negative breast cancer (TNBC) patients (pts). Journal of Clinical Oncology. 31: 1065-1065. DOI: 10.1200/Jco.2013.31.15_Suppl.1065 |
0.387 |
|
| 2013 |
Boucher Y, Martin JD, Tolaney SM, Seano G, Goel S, Ancukiewicz M, Isakoff SJ, Winer EP, Krop IE, Jain RK. Abstract LB-76: Tissue biomarkers and interstitial fluid pressure in a phase II study of preoperative (preop) bevacizumab (bev) followed by dose-dense doxorubicin (A)/cyclophosphamide (C)/paclitaxel (T) in combination with bev in HER2-negative operable breast cancer (BC) Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-76 |
0.372 |
|
| 2013 |
Goel S, Gupta N, Walcott BP, Snuderl M, Kesler CT, Vakoc BJ, Peterson RT, Padera TP, Duda DG, Fukumura D, Jain RK. Abstract C1: Functional normalization of the breast cancer vasculature through activation of Tie2 using a vascular-endothelial protein tyrosine phosphatase inhibitor. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C1 |
0.466 |
|
| 2012 |
Kodack DP, Chung E, Yamashita H, Incio J, Duyverman AM, Song Y, Farrar CT, Huang Y, Ager E, Kamoun W, Goel S, Snuderl M, Lussiez A, Hiddingh L, Mahmood S, et al. Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases. Proceedings of the National Academy of Sciences of the United States of America. 109: E3119-27. PMID 23071298 DOI: 10.1073/Pnas.1216078109 |
0.45 |
|
| 2012 |
Goel S, Fukumura D, Jain RK. Normalization of the tumor vasculature through oncogenic inhibition: an emerging paradigm in tumor biology. Proceedings of the National Academy of Sciences of the United States of America. 109: E1214. PMID 22550180 DOI: 10.1073/Pnas.1203794109 |
0.309 |
|
| 2012 |
Goel S, Wong AH, Jain RK. Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease. Cold Spring Harbor Perspectives in Medicine. 2: a006486. PMID 22393532 DOI: 10.1101/Cshperspect.A006486 |
0.322 |
|
| 2012 |
Tolaney SM, Duda DG, Boucher Y, Goel S, Martin J, Ancukiewicz M, Potler H, Incio J, Ligibel JA, Isakoff SJ, Fukumura D, Winer EP, Krop IE, Jain RK. A phase II study of preoperative (preop) bevacizumab (bev) followed by dose-dense (dd) doxorubicin (A)/cyclophosphamide (C)/paclitaxel (T) in combination with bev in HER2-negative operable breast cancer (BC). Journal of Clinical Oncology. 30: 1026-1026. DOI: 10.1200/Jco.2012.30.15_Suppl.1026 |
0.325 |
|
| 2012 |
Kodack D, Chung E, Yamashita H, Incio J, Peters A, Song Y, Ager E, Huang Y, Farrar C, Lussiez A, Goel S, Snuderl M, Kamoun W, Hiddingh L, Tannous B, et al. Abstract P3-12-03: Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases. Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P3-12-03 |
0.478 |
|
| 2011 |
Ghamande SA, Lin C, Cho DC, Coleman TA, Chaudhary I, Cleary JM, Silverman MH, Kuo M, Mach W, Tseng Y, Hsu SC, Goel S. A phase I study of the novel DNA topoisomerase-1 inhibitor, TLC388, administered intravenously to patients with advanced solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e13618. PMID 28023558 DOI: 10.1200/Jco.2011.29.15_Suppl.E13618 |
0.336 |
|
| 2011 |
Goel S, Lynch J, Chantrill LA, Rutovitz JJ, Murray B, Abdi EA, Bell R, Sullivan AL, Goldrick A, Hayes TM, Asghari G, Wilcken N, McCarthy NJ, Beith JM. Serum NT pro-BNP and individual genetic polymorphisms as predictors of trastuzumab-related cardiotoxicity. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: TPS121. PMID 28022939 DOI: 10.1200/Jco.2011.29.15_Suppl.Tps121 |
0.356 |
|
| 2011 |
Goel S, Simes RJ, Beith JM. Exploratory analysis of cardiac biomarkers in women with normal cardiac function receiving trastuzumab for breast cancer. Asia-Pacific Journal of Clinical Oncology. 7: 276-80. PMID 21884439 DOI: 10.1111/J.1743-7563.2011.01422.X |
0.303 |
|
| 2011 |
Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, Jain RK. Normalization of the vasculature for treatment of cancer and other diseases. Physiological Reviews. 91: 1071-121. PMID 21742796 DOI: 10.1152/Physrev.00038.2010 |
0.374 |
|
| 2011 |
Hiratsuka S, Goel S, Kamoun WS, Maru Y, Fukumura D, Duda DG, Jain RK. Endothelial focal adhesion kinase mediates cancer cell homing to discrete regions of the lungs via E-selectin up-regulation. Proceedings of the National Academy of Sciences of the United States of America. 108: 3725-30. PMID 21321210 DOI: 10.1073/Pnas.1100446108 |
0.355 |
|
| 2011 |
Goel S, Chirgwin J, Francis P, Stuart-Harris R, Dewar J, Mileshkin L, Snyder R, Michael M, Koczwara B. Rational use of trastuzumab in metastatic and locally advanced breast cancer: implications of recent research. Breast (Edinburgh, Scotland). 20: 101-10. PMID 21183347 DOI: 10.1016/J.Breast.2010.11.008 |
0.465 |
|
| 2011 |
Hiratsuka S, Duda DG, Huang Y, Goel S, Sugiyama T, Nagasawa T, Fukumura D, Jain RK. C-X-C receptor type 4 promotes metastasis by activating p38 mitogen-activated protein kinase in myeloid differentiation antigen (Gr-1)-positive cells. Proceedings of the National Academy of Sciences of the United States of America. 108: 302-7. PMID 21173223 DOI: 10.1073/Pnas.1016917108 |
0.351 |
|
| 2011 |
Liu J, Liao S, Diop B, Chen W, Goel S, Huang Y, Boucher Y, Jain RK, Xu L. Abstract 715: TGF-beta blockade improves the distribution and efficacy of chemotherapeutic agents in breast carcinoma Cancer Research. 71: 715-715. DOI: 10.1158/1538-7445.Am2011-715 |
0.339 |
|
| 2009 |
Goel S, Sharma R, Hamilton A, Beith J. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. The Cochrane Database of Systematic Reviews. CD004562. PMID 19821328 DOI: 10.1002/14651858.Cd004562.Pub4 |
0.412 |
|
| 2009 |
Goel S, Hamilton A. Cancer drugs in the real world Asia-Pacific Journal of Clinical Oncology. 5: 1-3. DOI: 10.1111/J.1743-7563.2009.01195.X |
0.312 |
|
| 2009 |
Goel S, Abdi E, Lewis CR, Links M, Begbie S, Clingan P, Ganju V, Beith J. Phase II study of gemcitabine and docetaxel in combination for the treatment of metastatic breast cancer Asia-Pacific Journal of Clinical Oncology. 5: 32-38. DOI: 10.1111/J.1743-7563.2009.01189.X |
0.416 |
|
| 2008 |
Goel S, Simes RJ, Beith JM. An exploratory analysis of cardiac biomarkers in women receiving trastuzumab Journal of Clinical Oncology. 26: 20557-20557. DOI: 10.1200/Jco.2008.26.15_Suppl.20557 |
0.36 |
|
| Show low-probability matches. |